Frederick, MD-based Vaccinogen has scored $10 million to fund work on its colon cancer candidate, OncoVax. A Stockholm-based investor group known as The Investment Syndicate put up the money, and Vaccinogen will receive another $70 million in four more payments. Vaccinogen is prepping a confirmatory Phase IIIb pivotal study of the patient-specific vaccine in patients with resectable, Stage 2 colon cancer. Release